HER2-Negative Breast Cancer Market Report 2026
Download Free Sample Buy Now
HER2-Negative Breast Cancer Market Global Report 2026 Market Report Infographic Image

Published : March 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

HER2-Negative Breast Cancer Market Report 2026

Global Outlook – By Treatment Type (Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy), By Cancer Stage (Early Stage, Locally Advanced Stage, Metastatic Stage), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Purchase This Report Download Sample PDF
Item added to cart!

HER2-Negative Breast Cancer Market Overview

• HER2-Negative Breast Cancer market size has reached to $17.57 billion in 2025

• Expected to grow to $25.41 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%

• Growth Driver: Rising Breast Cancer Incidence Drives Growth Of The Market

• Market Trend: Regulatory Approvals And Market Expansion In HER2-Negative Breast Cancer Treatments

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under HER2-Negative Breast Cancer Market?

HER2-negative breast cancer refers to a type of breast cancer where the cancer cells do not have high levels of the HER2 protein, which promotes tumour growth. This type of cancer tends to grow more slowly than HER2-positive breast cancer and is treated with targeted therapies and chemotherapy.

The main treatment types of HER2-negative breast cancer are chemotherapy, hormone therapy, targeted therapy, and immunotherapy. Chemotherapy refers to a type of cancer treatment that uses powerful drugs to kill or inhibit the growth of cancer cells by targeting and destroying rapidly dividing cells in the body. It includes different stages, including early stage, locally advanced stage, and metastatic stage, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

HER2-Negative Breast Cancer Market Global Report 2026 Market Report bar graph

What Is The HER2-Negative Breast Cancer Market Size and Share 2026?

The her2-negative breast cancer market size has grown strongly in recent years. It will grow from $17.57 billion in 2025 to $18.95 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increasing breast cancer screening rates, rising awareness of hormone receptor-positive cancers, expansion of oncology treatment centers, availability of established chemotherapy protocols, growth in clinical oncology research.

What Is The HER2-Negative Breast Cancer Market Growth Forecast?

The her2-negative breast cancer market size is expected to see strong growth in the next few years. It will grow to $25.41 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to increasing demand for personalized oncology treatments, rising adoption of genomic-driven therapies, expansion of immunotherapy pipelines, growing focus on improving progression-free survival, increasing investment in oncology drug development. Major trends in the forecast period include increasing adoption of personalized hormone therapy regimens, growing use of cdk4/6 inhibitors, expansion of genomic testing for treatment selection, rising integration of immunotherapy in advanced stages, enhanced focus on combination treatment protocols.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global HER2-Negative Breast Cancer Market Segmentation

1) By Treatment Type: Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy

2) By Cancer Stage: Early Stage, Locally Advanced Stage, Metastatic Stage

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Chemotherapy: Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites

2) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)

3) By Targeted Therapy: CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors

4) By Immunotherapy: Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy

What Is The Driver Of The HER2-Negative Breast Cancer Market?

Rising incidence of breast cancer cases is expected to propel the growth of the HER2-negative breast cancer market going forward. Breast cancer is a disease characterized by the uncontrolled growth of abnormal cells in the breast tissue, commonly originating in the ducts or lobules. The rising incidence of breast cancer cases can be attributed to several factors, including increased awareness and improved screening methods, leading to earlier and more frequent detection. HER2-Negative Breast Cancer plays a crucial role in advancing breast cancer research by providing insights into distinct tumor biology and treatment strategies, contributing to the development of more targeted therapies for patients. For instance, in 2025, according to the American Cancer Society, a US-based professional organization company, in 2025, the United States is projected to see approximately 316,950 new cases of invasive breast cancer in women and 2,800 cases in men, along with an estimated 59,080 cases of ductal carcinoma in situ (DCIS) diagnosed in women. Therefore, the rising incidence of breast cancer cases is driving the growth of the HER2-negative breast cancer industry.

Key Players In The Global HER2-Negative Breast Cancer Market

Major companies operating in the her2-negative breast cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

Global HER2-Negative Breast Cancer Market Trends and Insights

Major companies operating in the HER2-negative breast cancer market are focusing on securing regulatory approvals to introduce new treatments, expand their product portfolios, and enhance their market presence. Regulatory approvals refer to the official authorization granted by government agencies, allowing companies to market and distribute drugs or treatments after meeting safety, efficacy, and quality standards. For instance, in October 2024, Genentech Inc., a US-based biotechnology corporation, received FDA approval for Itovebi (inavolisib) as a targeted treatment for advanced hormone receptor-positive (HR+), HER2-negative breast cancer with a PIK3CA mutation. This approval allows Itovebi to be used in combination with palbociclib and fulvestrant, significantly improving progression-free survival for patients compared to standard treatments. This new regimen provides a vital option for patients facing limited treatment choices, emphasizing the importance of biomarker testing to identify those who would benefit most from this therapy.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The HER2-Negative Breast Cancer Market?

In June 2024, Relay Therapeutics Inc., a US-based clinical-stage precision medicine company, collaborated with Pfizer Inc. This collaboration is aimed at evaluating atirimociclib, Pfizer’s investigative selective CDK4 inhibitor, in combination with RLY-2608 and fulvestrant in patients with PI3Ka-mutated, HR+, HER2- metastatic breast cancer. This collaboration also aims to leverage the unique properties of both drugs to minimize off-target toxicity that has limited the efficacy of non-selective agents in the past. Pfizer Inc. is a US-based pharmaceutical and biotechnology corporation actively involved in the treatment of HER2-negative breast cancer.

Regional Outlook

North America was the largest region in the HER2-negative breast cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the HER2-Negative Breast Cancer Market?

The HER2-negative breast cancer market includes revenues earned by entities by providing services such as radiation therapy, genetic testing, mammography, and counseling and psychological support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the HER2-Negative Breast Cancer Market Report 2026?

The her2-negative breast cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the her2-negative breast cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

HER2-Negative Breast Cancer Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $18.95 billion
Revenue Forecast In 2035 $25.41 billion
Growth Rate CAGR of 7.9% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Treatment Type, Cancer Stage, Distribution Channel
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. HER2-Negative Breast Cancer Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global HER2-Negative Breast Cancer Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. HER2-Negative Breast Cancer Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global HER2-Negative Breast Cancer Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.2. Major Trends

4.2.1 Increasing Adoption Of Personalized Hormone Therapy Regimens

4.2.2 Growing Use Of Cdk4/6 Inhibitors

4.2.3 Expansion Of Genomic Testing For Treatment Selection

4.2.4 Rising Integration Of Immunotherapy In Advanced Stages

4.2.5 Enhanced Focus On Combination Treatment Protocols

5. HER2-Negative Breast Cancer Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Oncology Clinics

5.3 Cancer Research Institutes

5.4 Specialty Care Centers

5.5 Ambulatory Care Centers

6. HER2-Negative Breast Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global HER2-Negative Breast Cancer Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global HER2-Negative Breast Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global HER2-Negative Breast Cancer Market Size, Comparisons And Growth Rate Analysis

7.3. Global HER2-Negative Breast Cancer Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global HER2-Negative Breast Cancer Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global HER2-Negative Breast Cancer Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. HER2-Negative Breast Cancer Market Segmentation

9.1. Global HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy

9.2. Global HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Early Stage, Locally Advanced Stage, Metastatic Stage

9.3. Global HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

9.4. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Anthracyclines, Taxanes, Platinum-Based Chemotherapy, Alkylating Agents, Antimetabolites

9.5. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs)

9.6. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

CDK4/6 Inhibitors, PI3K Inhibitors, PARP Inhibitors

9.7. Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Immune Checkpoint Inhibitors, Tumor-Infiltrating Lymphocyte (TIL) Therapy

10. HER2-Negative Breast Cancer Market Regional And Country Analysis

10.1. Global HER2-Negative Breast Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global HER2-Negative Breast Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific HER2-Negative Breast Cancer Market

11.1. Asia-Pacific HER2-Negative Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China HER2-Negative Breast Cancer Market

12.1. China HER2-Negative Breast Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India HER2-Negative Breast Cancer Market

13.1. India HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan HER2-Negative Breast Cancer Market

14.1. Japan HER2-Negative Breast Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia HER2-Negative Breast Cancer Market

15.1. Australia HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia HER2-Negative Breast Cancer Market

16.1. Indonesia HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea HER2-Negative Breast Cancer Market

17.1. South Korea HER2-Negative Breast Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan HER2-Negative Breast Cancer Market

18.1. Taiwan HER2-Negative Breast Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia HER2-Negative Breast Cancer Market

19.1. South East Asia HER2-Negative Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe HER2-Negative Breast Cancer Market

20.1. Western Europe HER2-Negative Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK HER2-Negative Breast Cancer Market

21.1. UK HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany HER2-Negative Breast Cancer Market

22.1. Germany HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France HER2-Negative Breast Cancer Market

23.1. France HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy HER2-Negative Breast Cancer Market

24.1. Italy HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain HER2-Negative Breast Cancer Market

25.1. Spain HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe HER2-Negative Breast Cancer Market

26.1. Eastern Europe HER2-Negative Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia HER2-Negative Breast Cancer Market

27.1. Russia HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America HER2-Negative Breast Cancer Market

28.1. North America HER2-Negative Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA HER2-Negative Breast Cancer Market

29.1. USA HER2-Negative Breast Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada HER2-Negative Breast Cancer Market

30.1. Canada HER2-Negative Breast Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America HER2-Negative Breast Cancer Market

31.1. South America HER2-Negative Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil HER2-Negative Breast Cancer Market

32.1. Brazil HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East HER2-Negative Breast Cancer Market

33.1. Middle East HER2-Negative Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa HER2-Negative Breast Cancer Market

34.1. Africa HER2-Negative Breast Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Segmentation By Cancer Stage, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. HER2-Negative Breast Cancer Market Regulatory and Investment Landscape

36. HER2-Negative Breast Cancer Market Competitive Landscape And Company Profiles

36.1. HER2-Negative Breast Cancer Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. HER2-Negative Breast Cancer Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. HER2-Negative Breast Cancer Market Company Profiles

36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

37. HER2-Negative Breast Cancer Market Other Major And Innovative Companies

Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd.

38. Global HER2-Negative Breast Cancer Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The HER2-Negative Breast Cancer Market

40. HER2-Negative Breast Cancer Market High Potential Countries, Segments and Strategies

40.1 HER2-Negative Breast Cancer Market In 2030 - Countries Offering Most New Opportunities

40.2 HER2-Negative Breast Cancer Market In 2030 - Segments Offering Most New Opportunities

40.3 HER2-Negative Breast Cancer Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global HER2-Negative Breast Cancer Market, Overview Of Key Products - Product Examples
  • Table 2: Global HER2-Negative Breast Cancer Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global HER2-Negative Breast Cancer Market, Supply Chain Analysis
  • Table 4: Global HER2-Negative Breast Cancer Market, Major Raw Material Providers
  • Table 5: Global HER2-Negative Breast Cancer Market, Major Resource Providers
  • Table 6: Global HER2-Negative Breast Cancer Market, Major Manufacturers (Suppliers)
  • Table 7: Global HER2-Negative Breast Cancer Market, Major Distributors And Channel Partners
  • Table 8: Global HER2-Negative Breast Cancer Market, Key Technologies & Future Trends
  • Table 9: Global HER2-Negative Breast Cancer Market, Major Trends
  • Table 10: Global HER2-Negative Breast Cancer Market, Major End Users
  • Table 11: Global HER2-Negative Breast Cancer Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global HER2-Negative Breast Cancer Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global HER2-Negative Breast Cancer Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global HER2-Negative Breast Cancer Market - TAM, US$ Billion, 2025
  • Table 15: Global HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Global HER2-Negative Breast Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Global HER2-Negative Breast Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Asia-Pacific, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: Asia-Pacific, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: Asia-Pacific, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: China, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: China, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: China, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: India, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: India, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: India, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: Japan, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: Japan, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: Japan, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Australia, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Australia, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Australia, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Indonesia, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Indonesia, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: Indonesia, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: South Korea, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: South Korea, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: South Korea, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: Taiwan, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: Taiwan, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: Taiwan, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: South East Asia, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: South East Asia, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: South East Asia, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: Western Europe, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: Western Europe, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: Western Europe, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: UK, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: UK, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: UK, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: Germany, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: Germany, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: Germany, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: France, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: France, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: France, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: Italy, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: Italy, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Italy, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Spain, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Spain, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Spain, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Eastern Europe, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Eastern Europe, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Eastern Europe, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Russia, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: Russia, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: Russia, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: North America, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: North America, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: North America, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: USA, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: USA, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: USA, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: Canada, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: Canada, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: Canada, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: South America, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: South America, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: South America, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: Brazil, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: Brazil, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: Brazil, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Middle East, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Middle East, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Middle East, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Africa, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Africa, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 95: Africa, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 96: Global HER2-Negative Breast Cancer Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 97: Global HER2-Negative Breast Cancer Market - Company Scoring Matrix
  • Table 98: Pfizer Inc. Financial Performance
  • Table 99: Merck & Co. Inc. Financial Performance
  • Table 100: AbbVie Inc. Financial Performance
  • Table 101: Bayer AG Financial Performance
  • Table 102: Bristol-Myers Squibb Company Financial Performance
  • Table 103: Global HER2-Negative Breast Cancer Market, Competitive Benchmarking (In USD Billions)
  • Table 104: Global HER2-Negative Breast Cancer Market, Competitive Dashboard
  • Table 105: Global HER2-Negative Breast Cancer Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 106: Global, HER2-Negative Breast Cancer Market Size Gain ($ Billion), Segmentation By Treatment Type, 2025 – 2030
  • Table 107: Global, HER2-Negative Breast Cancer Market Size Gain ($ Billion), Segmentation By Cancer Stage, 2025 – 2030
  • Table 108: Global, HER2-Negative Breast Cancer Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

List Of Figures

    Figure 1: Global HER2-Negative Breast Cancer Market, Overview Of Key Products - Product Examples
  • Figure 2: Global HER2-Negative Breast Cancer Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global HER2-Negative Breast Cancer Market, Supply Chain Analysis
  • Figure 4: Global HER2-Negative Breast Cancer Market, Major Raw Material Providers
  • Figure 5: Global HER2-Negative Breast Cancer Market, Major Resource Providers
  • Figure 6: Global HER2-Negative Breast Cancer Market, Major Manufacturers (Suppliers)
  • Figure 7: Global HER2-Negative Breast Cancer Market, Major Distributors And Channel Partners
  • Figure 8: Global HER2-Negative Breast Cancer Market, Key Technologies & Future Trends
  • Figure 9: Global HER2-Negative Breast Cancer Market, Major Trends
  • Figure 10: Global HER2-Negative Breast Cancer Market, Major End Users
  • Figure 11: Global HER2-Negative Breast Cancer Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global HER2-Negative Breast Cancer Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global HER2-Negative Breast Cancer Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global HER2-Negative Breast Cancer Market - TAM, US$ Billion, 2025
  • Figure 15: Global HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global HER2-Negative Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Global HER2-Negative Breast Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Global HER2-Negative Breast Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Asia-Pacific, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: Asia-Pacific, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: Asia-Pacific, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: China, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: China, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: China, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: India, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: India, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: India, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: Japan, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: Japan, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: Japan, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Australia, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Australia, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Australia, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Indonesia, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Indonesia, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: Indonesia, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: South Korea, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: South Korea, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: South Korea, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: Taiwan, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: Taiwan, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: Taiwan, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: South East Asia, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: South East Asia, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: South East Asia, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: Western Europe, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: Western Europe, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: Western Europe, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: UK, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: UK, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: UK, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: Germany, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: Germany, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: Germany, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: France, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: France, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: France, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: Italy, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: Italy, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Italy, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Spain, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Spain, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Spain, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Eastern Europe, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Eastern Europe, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Eastern Europe, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Russia, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: Russia, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: Russia, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: North America, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: North America, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: North America, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: USA, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: USA, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: USA, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: Canada, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: Canada, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: Canada, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: South America, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: South America, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: South America, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: Brazil, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: Brazil, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: Brazil, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Middle East, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Middle East, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Middle East, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Africa, HER2-Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Africa, HER2-Negative Breast Cancer Market, Segmentation By Cancer Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 95: Africa, HER2-Negative Breast Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 96: Global HER2-Negative Breast Cancer Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 97: Global HER2-Negative Breast Cancer Market - Company Scoring Matrix
  • Figure 98: Pfizer Inc. Financial Performance
  • Figure 99: Merck & Co. Inc. Financial Performance
  • Figure 100: AbbVie Inc. Financial Performance
  • Figure 101: Bayer AG Financial Performance
  • Figure 102: Bristol-Myers Squibb Company Financial Performance
  • Figure 103: Global HER2-Negative Breast Cancer Market, Competitive Benchmarking (In USD Billions)
  • Figure 104: Global HER2-Negative Breast Cancer Market, Competitive Dashboard
  • Figure 105: Global HER2-Negative Breast Cancer Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 106: Global, HER2-Negative Breast Cancer Market Size Gain ($ Billion), Segmentation By Treatment Type, 2025 – 2030
  • Figure 107: Global, HER2-Negative Breast Cancer Market Size Gain ($ Billion), Segmentation By Cancer Stage, 2025 – 2030
  • Figure 108: Global, HER2-Negative Breast Cancer Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030

Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

Read More About Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Read More About Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

Read More About Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Read More About CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

Read More About Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Read More About Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Triple Negative Breast Cancer Market Report 2026 - Global Outlook – By Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, Surgery, Radiation Therapy, Other Treatment Types), By Type Of Test (Imaging Technique...

Breast Cancer Drugs Market Report 2026 - Global Outlook – By Type (Metastatic Breast Cancer, Triple Negative Breast Cancer, Other Types), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Othe...

Metastatic HR+/HER2- Breast Cancer Market Report 2026 - Global Outlook – By Drugs (Paclitaxel, Tamoxifen, Docetaxel, Other Drugs), By Treatment (Radiation Therapy, Vitamin Therapy, Macrobiotic Diets, Homeopathy, Herbal M...

Breast Cancer Diagnostics Market Report 2026 - Global Outlook – By Type (Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types), By Technology (Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridizati...

Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Report 2026 - Global Outlook – By Treatment (Hormonal Therapy, Chemoprevention, Genetic Counselling, Medication, Other Treatments), By Diagnosis (Genetic Tes...

Metastatic Breast Cancer Treatment Market Report 2026 - Global Outlook – By Therapy Type (Chemotherapy, Radiation Therapy, Biologic Targeted Therapy, Breast Surgery, Hormone Therapy), By Molecule Type (Monoclonal Antibod...

Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report 2026 - Global Outlook – By Therapy Type (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therap...

Anti-Cancer MAbS Market Report 2026 - Global Outlook – By Type (Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types), By Application (Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal C...

Frequently Asked Questions

The HER2-Negative Breast Cancer market was valued at $17.57 billion in 2025, increased to $18.95 billion in 2026, and is projected to reach $25.41 billion by 2030.

The global HER2-Negative Breast Cancer market is expected to grow at a CAGR of 7.6% from 2026 to 2035 to reach $25.41 billion by 2035.

Some Key Players in the HER2-Negative Breast Cancer market Include, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Daiichi Sankyo Company Limited, Jiangsu Hansoh Pharmaceutical Co. Ltd., BeiGene Ltd., Chipscreen Biosciences Ltd., F. Hoffmann-La Roche Ltd, PharmAbcine Inc., Adagene Inc., H3 Biomedicine Inc., Radius Health Inc., Zenith Epigenetics Ltd. .

Major trend in this market includes: Regulatory Approvals And Market Expansion In HER2-Negative Breast Cancer Treatments. For further insights on this market. request a sample here

North America was the largest region in the HER2-negative breast cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the her2-negative breast cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us